Grufity logoGrufity logo

INCY

83.13USD+2.45(+3.04%)Market Closed

Incyte Corp

Market Summary

USD83.13+2.45Market Closed
3.04%

INCY Alerts

INCY Stock Price

RSI Chart

Valuation

Market Cap

16.6B

Price/Earnings

17.56

Price/Sales

5

Price/Cashflow

21.82

MarketCap/EBT

26.36

Price/Sales

Profitability

Operating Margin

94.67%

EBT Margin

18.96%

Return on Equity

23.13%

Return on Assets

17.77%

Fundamentals

Revenue

Revenue (TTM)

3.3B

Revenue Y/Y

29.15%

Revenue Q/Q

24.3%

Earnings

Earnings (TTM)

876.0M

Earnings Y/Y

-37.95%

Earnings Q/Q

-30.14%

Price Action

52 Week Range

64.3284.86
(Low)(High)

Last 7 days

6.2%

Last 30 days

7.8%

Last 90 days

18.4%

Trailing 12 Months

24.8%

Financial Health

Current Ratio

3.91

Investor Care

Shares Dilution (1Y)

0.72%

Diluted EPS (TTM)

3.93

Peers (Alternatives to Incyte)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
99.4B
27.1B
14.32% 33.87%
24.02
3.61
-1.26% -54.91%
59.1B
23.0B
22.70% -39.52%
4.2
2.57
227.55% 302.16%
16.6B
3.3B
7.75% 24.76%
17.56
5
22.05% 63.88%
MID-CAP
6.1B
1.9B
40.44% -42.46%
-8.33
3.16
13.25% 11.39%
5.4B
1.6B
2.23% 5.52%
19.63
3.44
30.66% 87.25%
5.2B
5.4B
-28.76% -64.60%
18.72
0.96
8.57% 14.42%
3.8B
243.2M
-1.96% -51.31%
-24.67
15.19
75.89% -25.00%
3.7B
112.4M
6.18% -26.69%
-12.87
32.5
-41.50% -607.58%
SMALL-CAP
1.8B
1.8B
-19.41% -89.80%
-1.22
1.39
53.41% -22.97%
955.6M
3.3M
2.29% -33.20%
-21.05
291.16
-26.92% -26.56%
728.9M
60.3M
-14.86% -77.13%
-1.39
13.26
17.51% -38.87%
335.1M
75.9M
15.24% -52.63%
-3.66
4.15
9.61% 123.40%
19.1M
-
3.68% -62.86%
-2.32
-
- 22.78%
3.4M
-
1.85% -88.32%
-0.06
155.91
- -67.16%

Financials for Incyte

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue6.6%3,3203,1152,9862,9132,721
  S&GA Expenses10.6%880795740680
  R&D Expenses0.2%1,5081,5051,4581,391
Earnings Before Taxes10.1%629572570619
Net Income1.3%945933949535
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets3.6%5,5105,3195,0544,9334,199
  Current Assets5.4%3,8213,6263,2883,1192,924
    Cash Equivalents10.5%2,6922,4352,2572,0571,999
  Inventory-15.8%4655352821
  Net PPE-0.8%716721729724687
  Goodwill0%156156156156156
Liabilities4.0%1,2841,2341,1911,1631,050
  Current Liabilities8.6%1,007927886854743
Shareholder's Equity3.5%4,2274,0853,8633,7703,149
  Retained Earnings19.5%-465.67-578.45-739.88-777.87-1,341.72
  Additional Paid-In Capital1.4%4,6894,6264,5674,509-
Accumulated Depreciation5.3%202192186176168
Shares Outstanding0.3%222222221221221
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations5.4%802760759749741
  Share Based Compensation1.5%184181180183180
Cashflow From Investing3.4%-123.68-128.03-164.69-207.70-244.38
Cashflow From Financing88.9%116-6.5669

Risks

What is the probability of a big loss on INCY?

82.3%


Probability that Incyte stock will be more than 20% underwater in next one year

30.4%


Probability that Incyte stock will be more than 30% underwater in next one year.

16.5%


Probability that Incyte stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does INCY drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Incyte was unfortunately bought at previous high price.

Returns

Cumulative Returns on INCY

16.7%


10-Year Cumulative Returns

-3.8%


7-Year Cumulative Returns

-3.2%


5-Year Cumulative Returns

-4.0%


3-Year Cumulative Returns

What are the long-term rolling returns for INCY?

FIve years rolling returns for Incyte.

Which funds bought or sold INCY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
NEW
-
265,000
265,000
0.27%
2022-11-23
Eagle Bay Advisors LLC
UNCHANGED
-
88
1,000
-%
2022-11-23
Toroso Investments, LLC
ADDED
12.29
-13,000
830,000
0.03%
2022-11-22
CVA Family Office, LLC
UNCHANGED
-
-3,000
23,000
0.01%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
1,132,000
1,132,000
0.01%
2022-11-22
B. Riley Wealth Advisors, Inc.
REDUCED
-0.58
-31,000
217,000
0.01%
2022-11-21
FourThought Financial, LLC
UNCHANGED
-
-9,000
67,000
0.01%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
REDUCED
-0.31
-3,025,000
21,077,000
0.04%
2022-11-18
National Pension Service
REDUCED
-2.27
-3,472,000
20,791,000
0.04%
2022-11-17
M&T Bank Corp
ADDED
19.68
113,000
930,000
-%

1–10 of 45

Latest Funds Activity

Are funds buying INCY calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own INCY

Incyte News

Seeking Alpha

BBH: Portfolio Of Large-Cap Biotechnology Stocks Has Delivered Strong Returns.26 hours ago

INCY Fair Value

Recent SEC filings of Incyte

View All Filings
Date Filed Form Type Document
Nov 01, 2022
10-Q
Quarterly Report
Nov 01, 2022
8-K
Current Report
Oct 20, 2022
4
Insider Trading
Oct 05, 2022
4
Insider Trading
Oct 05, 2022
3
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
4
Insider Trading
Oct 04, 2022
8-K
Current Report
Oct 04, 2022
4
Insider Trading

Latest Insider Trading transactions for INCY

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-10-19
HARRIGAN EDMUND
ACQUIRED
11,482.3
69.59
165
-
2022-07-22
Tray Thomas
SOLD
-130,015
83.13
-1,564
Principal Accounting Officer
2022-07-07
Iyengar Vijay K
SOLD
-459,372
79.38
-5,787
EVP, GMAPPS
2022-07-07
Flannelly Barry P
SOLD
-228,059
79.38
-2,873
EVP & General Manager US
2022-07-05
Hoppenot Herve
SOLD (Taxes)
-1,678,040
79.25
-21,174
Chairman / CEO
2022-07-05
Pasquale Maria E
SOLD (Taxes)
-241,158
79.25
-3,043
EVP & General Counsel
2022-07-05
Tray Thomas
SOLD (Taxes)
-78,219.8
79.25
-987
Principal Accounting Officer
2022-07-05
Flannelly Barry P
SOLD (Taxes)
-277,850
79.25
-3,506
EVP & General Manager US
2022-07-05
SWAIN PAULA J
SOLD (Taxes)
-205,971
79.25
-2,599
EVP, Human Resources
2022-07-05
Stein Steven H
SOLD (Taxes)
-305,588
79.25
-3,856
EVP & Chief Medical Officer

1–10 of 50

Herve Hoppenot
2090
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

INCY Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Total revenues$ 823,303$ 812,987$ 2,467,935$ 2,123,414
Costs and expenses:    
Cost of product revenues (including definite-lived intangible amortization)54,58439,869147,834107,117
Research and development384,007334,9451,084,576985,352
Selling, general and administrative266,460190,704729,321513,358
(Gain) loss on change in fair value of acquisition-related contingent consideration(21,893)2,910(12,198)13,068
Collaboration loss sharing1,7699,1499,05529,476
Total costs and expenses684,927577,5771,958,5881,648,371
Income from operations138,376235,410509,347475,043
Other income (expense), net11,5131,94813,2954,931
Interest expense(641)(439)(1,999)(1,156)
Unrealized loss on long term investments(660)(27,450)(72,142)(28,394)
Income before provision for income taxes148,588209,469448,501450,424
Provision for income taxes35,81327,730136,30265,694
Net income$ 112,775$ 181,739$ 312,199$ 384,730
Net income per share:    
Basic (in USD per share)$ 0.51$ 0.82$ 1.41$ 1.75
Diluted (in USD per share)$ 0.50$ 0.82$ 1.40$ 1.73
Shares used in computing net income per share:    
Basic (in shares)222,415220,845221,801220,243
Diluted (in shares)224,175222,248223,626222,113
Product revenues, net    
Revenues:    
Total revenues$ 713,010$ 594,013$ 1,982,682$ 1,673,974
Product royalty revenues    
Revenues:    
Total revenues110,293183,974350,253404,440
Milestone and contract revenues    
Revenues:    
Total revenues$ 0$ 35,000$ 135,000$ 45,000

INCY Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 2,690,622,000$ 2,057,440,000
Marketable securities—available-for-sale (amortized cost $292,941 and $291,871 as of September 30, 2022 and December 31, 2021, respectively; allowance for credit losses $0 as of September 30, 2022 and December 31, 2021)286,500,000290,752,000
Accounts receivable618,188,000616,300,000
Inventory45,869,00027,904,000
Prepaid expenses and other current assets179,932,000126,278,000
Total current assets3,821,111,0003,118,674,000
Restricted cash and investments1,601,0001,720,000
Long-Term Investments149,124,000221,266,000
Inventory55,264,00029,034,000
Property and equipment, net715,733,000723,920,000
Finance lease right-of-use assets, net26,679,00027,548,000
Other intangible assets, net134,603,000150,755,000
Goodwill155,593,000155,593,000
Deferred income tax asset426,840,000467,538,000
Other assets, net23,666,00037,304,000
Total assets5,510,214,0004,933,352,000
Current liabilities:  
Accounts payable163,175,000172,110,000
Accrued compensation106,309,000108,962,000
Accrued and other current liabilities699,814,000533,595,000
Finance lease liabilities3,112,0002,635,000
Acquisition-related contingent consideration34,186,00037,006,000
Total current liabilities1,006,596,000854,308,000
Acquisition-related contingent consideration171,814,000206,994,000
Finance lease liabilities30,476,00031,632,000
Other liabilities74,677,00070,414,000
Total liabilities1,283,563,0001,163,348,000
Commitments and contingencies (Note 14)
Stockholders’ equity:  
Preferred stock, $0.001 par value; 5,000,000 shares authorized; none issued or outstanding00
Common stock, $0.001 par value; 400,000,000 shares authorized; 222,454,839 and 221,084,433 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively222,000221,000
Additional paid-in capital4,721,166,0004,567,111,000
Accumulated other comprehensive loss(29,062,000)(19,454,000)
Accumulated deficit(465,675,000)(777,874,000)
Total stockholders’ equity4,226,651,0003,770,004,000
Total liabilities and stockholders’ equity$ 5,510,214,000$ 4,933,352,000